Multiple reports indicate the U.S. Food and Drug Administration is considering adding boxed (black box) warnings to Covid-19 vaccines; agency insiders and outside experts have publicly debated the move. One report attributes the initiative to senior FDA officials, while other outlets and experts cautioned the evidence base does not support such a sweeping regulatory action. Media coverage quotes FDA and HHS spokespeople stressing that no final decision has been announced and urging caution. The potential regulatory change would be unprecedented for widely used vaccines and could materially affect uptake and public confidence; stakeholders in pharma, public health and clinical practice are watching for formal agency communications and supporting data.